Teva's laquinimod fails Phase III RRMS study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis. Teva said it has "no current plans" to further develop the product for the indication.

The partners said laquinimod failed to improve time to confirmed disability progression (CDP) after at least three months vs. placebo (HR=0.937; p=0.7057), missing the primary endpoint. It also missed secondary endpoints evaluating time to CDP at six and nine months...